ライフサイエンスコーパス: CAR-T cell therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 cilitate safer application of effective CD19 CAR T-cell therapy.

2 ncing CRS and other adverse events following CAR T-cell therapy.

3 inued for 7.5 months after the initiation of CAR T-cell therapy.

4 ed and refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.

5 nical trials and inform the design of future CAR T cell therapies.

6 ective strategy for improving the potency of CAR T cell therapies.

7 data illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against mul

8 d of enormous preclinical efforts to develop CAR T-cell therapy beyond B-cell malignancies.

9 unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible danger

10 ion strategies to augment the feasibility of CAR T-cell therapy for patients with AML.

11 inical success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a

12 Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the m

13 Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in c

14 the bone marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cel

15 mplications for the development of effective CAR T cell therapies in cancer patients.

16 ese devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect agai

17 he application of chimeric antigen receptor (CAR) T cell therapy in cancers.

18 i-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic

19 We also discuss the outlook for CAR T-cell therapies, including managing toxicities and

20 e, as well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatmen

21 CD19-CAR T cell therapy is feasible, safe, and mediates poten

22 ever, in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cel

23 Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against

24 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires rob

25 efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-rela

26 dicate that FRbeta is a promising target for CAR T-cell therapy of AML, which may be augmented by com

27 ned disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored.

28 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with re

29 The ability of CAR T cell therapy to eliminate tumor was moderately imp

30 s the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid t

31 efractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durab

32 esized that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor re

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。